Lexaria Bioscience LEXX
NASDAQ LEXX
$2.82 +0.17 (+6.42%)
At close: Oct 21, 2026 · 4:00 PM EDT

Lexaria Bioscience (LEXX) Current Deferred Revenue (2016 - 2024)

Updated

Lexaria Bioscience's Current Deferred Revenue was $4,963 in fiscal Q4 2024 (quarter ended Aug 31, 2024).

Analysis

Lexaria Bioscience (LEXX) Current Deferred Revenue (2016 - 2024) Analysis & Trends

From fiscal Q3 2016 onward, Lexaria Bioscience has reported Current Deferred Revenue for 9 quarters.

  • The fiscal Q4 2024 figure marks the highest quarterly Current Deferred Revenue since fiscal Q1 2018.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Lexaria Bioscience 2.58 Mn -12.67 Mn -
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2024 4,963.00
Feb 28, 2023 4,275.00
Nov 30, 2017 10,833.00
Aug 31, 2017 17,083.00
May 31, 2017 19,600.00
Feb 28, 2017 24,969.00
Nov 30, 2016 21,150.00
Aug 31, 2016 12,500.00
May 31, 2016 8,819.00
API Access

Lexaria Bioscience Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=LEXX&period=max&api_key=YOUR_API_KEY